-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $18

Benzinga·06/02/2026 15:00:52
Listen to the news
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $15 to $18.